48 Week Data on Investigational Antiretroviral TMC125 From Tibotec
Toronto (ots/PRNewswire) - - TMC125 a Next-Generation NNRTI Tibotec Pharmaceuticals Ltd. presented 48 week efficacy and safety data on TMC125, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), at the 16th International AIDS conference (IAC), AIDS 2006, in Toronto, Canada this week. TMC125 is currently being investigated in phase 3 trials (DUET 1 and 2) in treatment-experienced adult ...